Herceptin (NSC #688097) and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/NEU
- Determine the response rate and survival of patients with metastatic pancreatic cancer
and overexpression of HER2/neu treated with gemcitabine and trastuzumab.
- Determine the toxic effects of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive gemcitabine IV over 30 minutes once weekly during weeks 1-7. Patients
receive trastuzumab IV over 90 minutes once during week 1 and trastuzumab IV over 30-90
minutes once weekly during weeks 2-8.
Patients with stable or responding disease receive gemcitabine IV over 30 minutes once
weekly during weeks 1-3 and trastuzumab IV over 30 minutes once weekly during weeks 1-4.
Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year and then every 6 months thereafter.
PROJECTED ACCRUAL: A maximum of 41 patients will be accrued for this study over 18-24
Primary Purpose: Treatment
Howard Safran, MD
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|
|University of Texas - MD Anderson Cancer Center||Houston, Texas 77030-4009|
|Rush-Presbyterian-St. Luke's Medical Center||Chicago, Illinois 60612|
|Rhode Island Hospital||Providence, Rhode Island 02903|
|Mount Sinai Medical Center, NY||New York, New York 10029|
|New England Medical Center Hospital||Boston, Massachusetts 02111|
|University of Pittsburgh Cancer Institute||Pittsburgh, Pennsylvania 15213|
|Roger Williams Medical Center/BUSM||Providence, Rhode Island 02908-4735|
|Cancer Institute of New Jersey||New Brunswick, New Jersey 08901|
|Brown University Oncology Group||Providence, Rhode Island 02912|
|St. Elizabeth's Medical Center||Boston, Massachusetts 02135-2997|
|Memorial Hospital of Rhode Island||Pawtucket, Rhode Island 02860|